Opus Genetics Inc. (IRD) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 39.7 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IRD currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.47) and Max Pain ($3.83) forces dealer call-delta covering toward $7.42.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Opus Genetics Inc. (IRD) slipped -0.81% to $3.65, trading at 36% of its 52-week range ($1.7 – $7.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Appointments strengthen scientific leadership and operational capabilities as Opus advances its pipeline of gene therapies for inherited retinal diseasesRESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opu
Opus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an invest
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index down 0.7% and the Sta
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhood Strategic collab
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childhoodStrategic
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +29.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IRD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IRD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Opus Genetics Inc. (IRD) ranks #891 by composite RQD confidence (32/100, grade E) and #517 by equity capitalization ($303.7M). Within this direct 5-issuer industry benchmark cohort, IRD leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with IRD at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRD
ACTIVE
Opus Genetics Inc. | E | 32/100 | — | — | -35.0% | -0.81% | $303.7M | Benchmark Subject |
| BNTC Benitec Biopharma Inc. | D- | 37/100 | — | — | -35.0% | +0.34% | $308.1M | /bntc-vs-ird → |
| VOGX Vogenx Inc | D+ | 56/100 | — | — | — | +5.29% | $295.9M | /vogx-vs-ird → |
| FULC Fulcrum Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +0.53% | $288.0M | /fulc-vs-ird → |
| ENTA Enanta Pharmaceuticals Inc. | E | 25/100 | — | — | -35.0% | -3.46% | $324.7M | /enta-vs-ird → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Opus Genetics Inc. (IRD) reported GAAP revenue of $14.2M (+29.1% vs. FY2024 revenue of $11.0M , and -25.5% cumulative change since FY2023) , GAAP net income of -$49.6M, operating cash flow of -$35.3M, and free cash flow of -$35.3M (-37.8% YoY). On the balance sheet, IRD closed FY2025 with $50.2M in total assets against $1.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.2M | -$49.6M | -$35.3M | -$35.3M | $50.2M | $1.1M |
| FY2024 (FY) | 2024-12-31 | $11.0M | -$57.5M | -$25.6M | -$25.6M | $36.9M | $0 |
| FY2023 (FY) | 2023-12-31 | $19.0M | -$10.0M | -$1.1M | -$1.1M | — | — |
As of 2026-11-01, Opus Genetics Inc. (NASDAQ: IRD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.65 (-0.81% 1D, market cap $303.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IRD ranks #891 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRD carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BNTC (Benitec Biopharma Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $308.1M) and VOGX (Vogenx Inc) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $295.9M). Among the 5-stock peer group, IRD leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).
Per IRD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001228627), Opus Genetics Inc. generated $14.2M in revenue (+29.1% YoY), -$49.6M in net income, and -$35.3M in free cash flow against $50.2M in total assets and $1.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IRD last traded at $3.65 (-0.81% on volume of 709,609 shares), positioning the stock -18.34% below its 50-day simple moving average ($4.47) and -12.68% below its 200-day simple moving average ($4.18). Across its 52-week range of $1.70 to $7.07, IRD sits at the 36.3% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.19 to $4.11).
Why IRD Stock slipped -0.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.